Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: An open-label study

Fertility and Sterility

Volumn 101, Issue 2, 2014, Pages 496-500

  Yerushalmi, Gil M ^a,c   Gilboa, Yinon ^a,c   Jakobson Setton, Ariella ^a,c   Tadir, Yona ^b,c   Goldchmit, Chen ^b,c   Katz, Danny ^d   Seidman, Daniel S ^a,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d Kupat Cholim Leumit   (Israel)

Author keywords

antiprogestins; fibroid; leiomyoma; Mifepristone

Indexed keywords

ANTIPROGESTINS; FIBROID; LEIOMYOMA; MIFEPRISTONE;

ADMINISTRATION, INTRAVAGINAL; ADULT; FEMALE; HORMONE ANTAGONISTS; HUMANS; ISRAEL; LEIOMYOMA; MIDDLE AGED; MIFEPRISTONE; PROSPECTIVE STUDIES; QUESTIONNAIRES; TREATMENT OUTCOME; UTERINE NEOPLASMS;

EID: 84895077060     PISSN: 00150282     EISSN: 15565653     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2013.10.015     Document Type: Article

References (25)

1. E.E. Wallach, and N.F. Vlahos Uterine myomas: an overview of development, clinical features, and management Obstet Gynecol 104 2004 393 406
2. W.H. Parker Uterine myomas: management Fertil Steril 88 2007 255 271
3. A.J. Friedman, R.L. Barbieri, P.M. Doubilet, C. Fine, and I. Schiff A randomized, double-blind trial of a gonadotropin releasing-hormone agonist (leuprolide) with or without medroxyprogesterone acetate in the treatment of leiomyomata uteri Fertil Steril 49 1988 404 409
4. U.S. Sangkomkamhang, P. Lumbiganon, M. Laopaiboon, and B.W. Mol Progestogens or progestogen-releasing intrauterine systems for uterine fibroids Cochrane Database Syst Rev 2 2013 CD008994
5. M. Tristan, L.J. Orozco, A. Steed, A. Ramirez-Morera, and P. Stone Mifepristone for uterine fibroids Cochrane Database Syst Rev 8 2012 CD007687
6. J. Donnez, T.F. Tatarchuk, P. Bouchard, L. Puscasiu, N.F. Zakharenko, and T. Ivanova et al. Ulipristal acetate versus placebo for fibroid treatment before surgery N Engl J Med 366 2012 409 420
7. J. Donnez, J. Tomaszewski, F. Vazquez, P. Bouchard, B. Lemieszczuk, and F. Baro et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids N Engl J Med 366 2012 421 432
8. O. Heikinheimo, H. Croxatto, A.M. Salvatierra, C.C. Chang, T. Luukkainen, and P. Lahteenmaki Intravaginal administration of RU 486 in humans and rats: inadequate absorption in humans Hum Reprod 2 1987 645 648
9. D. De Ziegler, C. Bulletti, B. De Monstier, and A.S. Jaaskelainen The first uterine pass effect Ann N Y Acad Sci 828 1997 291 299
10. C. Bulletti, D. de Ziegler, C. Flamigni, E. Giacomucci, V. Polli, and G. Bolelli et al. Targeted drug delivery in gynaecology: the first uterine pass effect Hum Reprod 12 1997 1073 1079
11. J.B. Spies, K. Coyne, N. Guaou Guaou, D. Boyle, K. Skyrnarz-Murphy, and S.M. Gonzalves The UFS-QoL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata Obstet Gynecol 99 2002 290 300
12. G. Harding, K.S. Coyne, C.L. Thompson, and J.B. Spies The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QoL) Health Qual Life Outcomes 6 2008 99
13. J.L. Carbonell Esteve, A.M. Riveron, M. Cano, A.I. Ortiz, A. Valle, and C.S. Texido et al. Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery Int J Womens Health 4 2012 75 84
14. S.H. Eisinger, J. Fiscella, T. Bonfiglio, S. Meldrum, and K. Fiscella Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata Eur J Obstet Gynecol Reprod Biol 146 2009 215 218
15. A.A. Murphy, A.J. Morales, L.M. Kettel, and S.S. Yen Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect Fertil Steril 64 1995 187 190
16. M. Bagaria, A. Suneja, N.B. Vaid, K. Guleria, and K. Mishra Low-dose mifepristone in treatment of uterine leiomyoma: a randomised double-blind placebo-controlled clinical trial Aust N Z J Obstet Gynaecol 49 2009 77 83
17. J.L. Esteve, R. Acosta, Y. Perez, R. Campos, A.V. Hernandez, and C.S. Texido Treatment of uterine myoma with 5 or 10mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial Eur J Obstet Gynecol Reprod Biol 161 2012 202 208
18. S. Mukherjee, and S. Chakraborty A study evaluating the effect of mifepristone (RU-486) for the treatment of leiomyomata uteri Niger Med J 52 2011 150 152
19. J. Steinauer, E.A. Pritts, R. Jackson, and A.F. Jacoby Systematic review of mifepristone for the treatment of uterine leiomyomata Obstet Gynecol 103 2004 1331 1336
20. J. Rabinovici, Y. Inbar, A. Revel, Y. Zalel, J.M. Gomori, and Y. Itzchak et al. Clinical improvement and shrinkage of uterine fibroids after thermal ablation by magnetic resonance-guided focused ultrasound surgery Ultrasound Obstet Gynecol 30 2007 771 777
21. R. Machtinger, Y. Inbar, S. Cohen-Eylon, D. Admon, A. Alagem-Mizrachi, and J. Rabinovici MR-guided focus ultrasound (MRgFUS) for symptomatic uterine fibroids: predictors of treatment success Hum Reprod 27 2012 3425 3431
22. J.L. Carbonell Esteve, R. Acosta, B. Heredia, Y. Perez, M.C. Castaneda, and A.V. Hernandez Mifepristone for the treatment of uterine leiomyomas: a randomized controlled trial Obstet Gynecol 112 2008 1029 1036
23. A.V. Hoekstra, E.C. Sefton, E. Berry, Z. Lu, J. Hardt, and E. Marsh et al. Progestins activate the AKT pathway in leiomyoma cells and promote survival J Clin Endocrinol Metab 94 2009 1768 1774
24. S.H. Eisinger, T. Bonfiglio, K. Fiscella, S. Meldrum, and D.S. Guzick Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas J Minim Invasive Gynecol 12 2005 227 233
25. M. Engman, S. Granberg, A.R. Williams, C.X. Meng, P.G. Lalitkumar, and K. Gemzell-Danielsson Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial Hum Reprod 24 2009 1870 1879